قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Teva can get up to 4BB in opioid market related injuries in the US – UBS – Teva Pharmaceutical Industries Limited (NYSE: TEVA)

Teva can get up to 4BB in opioid market related injuries in the US – UBS – Teva Pharmaceutical Industries Limited (NYSE: TEVA)



Teva Pharmaceutical Industries (TEVA -5% ) is down in the early trading on the heel with a downgrade to Neutral and $ 12 price targets at UBS after the company announced a $ 85m. Settlement with Oklahoma. Analyst Navin Jacob believes that the company could have a lot like a $ 4B exposure with the remaining plaintiffs who have filed complaints about certain painkillers for their role in the opioid crisis. The company and its subsidiaries face 1,500 lawsuits over their promotional activities of the addictive substances. A highly anticipated trial in Ohio starts in October.

Teva is also famous in a US trial of alleged pricing of generic drugs that could result in $ 600 million. ̵

1; EUR 3,200 million In further damage according to Mr. Jacob. 19659002] JPMorgan's Chris Schott and Leerink's Ami Fadia share UBS's cautious outlook on the company, but Raymond James & # 39; Elliot Wilbur (Outperform 2) are not worried and say, "Any settlement would be reasonable for the company's underlying cash flow generation" adds that Teva was "unequivocally motivated" to settle in Oklahoma.

SA Authors Rating is very Bullish. Quant Rating is very Bearish and the current Sell-Side Rating is Hold.


Source link